Black Cohosh

In vitro studies show black cohosh ethanolic extract inhibits CYP2D6 (IC50 50.1 µg/mL) and CYP3A4 (IC50 16.5 µg/mL), reducing formation of tamoxifen active metabolites: 4-hydroxytamoxifen by 66.3%, N-desmethyl tamoxifen by 74.6%, and alpha-hydroxytamoxifen by 80.3%. Alkaloids protopine and allocryptopine competitively inhibit CYP2D6 (Ki 78 nM and 122 nM). In a 28-day clinical study, black cohosh produced a modest ~7% statistically significant reduction in CYP2D6 phenotype. Tamoxifen anti-cancer efficacy depends on CYP2D6-mediated conversion to the active metabolite endoxifen; inhibition of this pathway may compromise therapeutic outcomes.

Advise breast cancer patients on tamoxifen to avoid black cohosh supplements, especially given its common use for tamoxifen-related hot flashes. If a patient insists on combining, consider monitoring tamoxifen metabolite (endoxifen) levels. CYP2D6 poor metabolizers are at particular risk. Discuss safer alternatives for menopausal symptom management such as venlafaxine or gabapentin.

In vitro evidence demonstrates that black cohosh extract modestly inhibits the organic anion-transporting polypeptide OATP2B1, a drug transporter expressed in the small intestine and liver responsible for uptake of numerous drugs. Inhibition of OATP2B1 can reduce the oral bioavailability and systemic exposure of its substrates, including statin medications (atorvastatin, fluvastatin, rosuvastatin), the antihistamine fexofenadine, the antidiabetic glyburide, and the antiarrhythmic amiodarone. Multiple human clinical trials have confirmed that black cohosh does not significantly affect CYP3A4, CYP2D6 (at standard doses), or P-glycoprotein, making OATP2B1 its primary clinically relevant drug transporter interaction.

Caution patients on statin therapy about the potential for modest reduction in statin effectiveness. Consider separating dosing of black cohosh from statin medications by at least 2-4 hours. For glyburide users, monitor blood glucose more closely when starting black cohosh. Clinical significance is considered low based on in vitro data only; human pharmacokinetic confirmation is lacking.

Black cohosh has been associated with rare but documented cases of hepatotoxicity, including elevated liver enzymes, cholestatic hepatitis, and acute liver failure. Over 75 cases of black cohosh-associated hepatotoxicity have been reported worldwide, though causality remains debated. The mechanism may involve immune-mediated reactions, metabolic idiosyncrasy, or direct hepatocellular toxicity. Co-administration with independently hepatotoxic medications creates additive hepatic burden and may precipitate or exacerbate liver injury.

Avoid combining black cohosh with known hepatotoxic drugs unless clinically necessary. Obtain baseline liver function tests (ALT, AST, ALP, bilirubin) before initiating black cohosh in at-risk patients and monitor periodically. Advise patients with pre-existing liver disease to avoid black cohosh entirely. Discontinue immediately if signs of hepatotoxicity develop (jaundice, dark urine, right upper quadrant pain, fatigue).

Black cohosh is used for menopausal symptom relief and may exert mixed estrogenic and anti-estrogenic pharmacodynamic effects through selective estrogen receptor modulation and central serotonergic activity (N-methylserotonin identified as active constituent). The net pharmacodynamic interaction with exogenous estrogens is tissue-specific and uncertain. Concurrent use in hormone-receptor-positive breast cancer patients receiving hormone therapy is of particular concern, as the estrogenic properties of black cohosh could theoretically stimulate estrogen-sensitive tissue.

In women using HRT, advise that black cohosh is typically redundant and may have unpredictable additive or antagonistic hormonal effects. In women with hormone-receptor-positive cancers or those taking aromatase inhibitors, black cohosh use should be explicitly discussed with the oncologist before initiation. Monitor for recurrence of symptoms or unexpected hormonal effects.

Black cohosh supplementation produced a small but statistically significant ~7% inhibition of CYP2D6 phenotype in healthy volunteers over 28 days (Gurley 2005). Alkaloids protopine and allocryptopine were identified as competitive CYP2D6 inhibitors with Ki values of 78 nM and 122 nM respectively in vitro. While the clinical magnitude of this inhibition is unlikely to be significant for most CYP2D6 substrates, narrow therapeutic index drugs (e.g., codeine, metoprolol, tricyclics) and CYP2D6 poor metabolizers may be more susceptible. CYP2D6 accounts for metabolism of ~25-30% of all drugs.

The interaction is unlikely to be clinically significant at standard black cohosh doses based on the ~7% in vivo CYP2D6 effect. However, monitor for altered drug effects in patients on CYP2D6-sensitive medications with narrow therapeutic windows. Exercise particular caution with prodrug codeine (reduced opioid analgesia) and metoprolol (increased beta-blockade/bradycardia). Report to prescriber if any unexpected drug effects occur.

Black cohosh extracts contain triterpene glycosides and other constituents that have demonstrated mild GABAergic activity and serotonin receptor interactions in preclinical studies. These CNS-modulating properties may potentiate the sedative effects of benzodiazepines, z-drugs, opioids, and barbiturates via additive CNS depression. A case report of bradycardia in a patient taking black cohosh also suggests possible cardiovascular CNS interactions. The pharmacodynamic interaction is concentration-dependent and most relevant at high black cohosh doses.

Advise patients to avoid combining black cohosh with CNS depressant medications, particularly sedative/hypnotics and opioids. Monitor for excessive sedation, respiratory depression, and falls in elderly patients. If combination is unavoidable, use the lowest effective dose of each agent. This combination is of particular concern in the perioperative setting.

Black cohosh is associated with rare but serious idiosyncratic hepatotoxicity, with over 75 global case reports including cases requiring liver transplantation. The mechanism is believed to involve immune-mediated or reactive metabolite-mediated liver injury rather than direct hepatotoxicity. Certain antifungal agents (ketoconazole, itraconazole, terbinafine) are also independently associated with hepatotoxicity. Co-administration creates additive risk of liver injury and may obscure the aetiology of liver function test abnormalities.

Avoid combining black cohosh with hepatotoxic antifungal agents. If antifungal therapy is required, discontinue black cohosh. Monitor liver function tests (ALT, AST, ALP, bilirubin) at baseline and during therapy if combination has occurred. Discontinue black cohosh immediately if LFTs are elevated and seek medical evaluation.

In vitro studies suggest black cohosh extracts may enhance cytotoxicity of doxorubicin and docetaxel against certain cancer cell lines via synergistic antiproliferative mechanisms. However, this same enhancement could increase chemotherapy toxicity against normal tissues. Black cohosh also inhibits CYP3A4 and CYP2D6 in vitro, potentially reducing docetaxel and doxorubicin clearance and increasing drug exposure. Additionally, both doxorubicin and black cohosh have hepatotoxic potential, creating additive liver injury risk.

Patients undergoing chemotherapy with doxorubicin or taxanes should avoid black cohosh unless under oncology supervision. The CYP3A4 inhibitory potential of black cohosh may increase docetaxel plasma levels and toxicity. Advise oncology patients to disclose all herbal supplement use. Discontinue black cohosh at least 2 weeks before starting chemotherapy.

Actein and 27-deoxyactein, triterpene glycosides in black cohosh, have demonstrated vasodilatory effects in animal models. Actein produces hypotensive effects through peripheral vasodilation, which may be additive with antihypertensive medications. Black cohosh triterpenes also have serotonergic receptor affinity, which could influence vascular tone. A case report documented bradycardia in a patient taking black cohosh, suggesting potential cardiovascular effects that may be relevant in patients on rate-controlling antihypertensives.

Monitor blood pressure and heart rate in patients combining black cohosh with antihypertensive therapy, particularly beta-blockers or calcium channel blockers. Advise elderly patients of fall risk from additive hypotensive effects. This interaction is low risk at standard black cohosh doses but warrants awareness.